A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination with the PARP inhibitor Talazoparib in Patients with Advanced or Metastatic Solid Tumors
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Sponsor: Calithera Biosciences, Inc
Enrolling: Male and Female Patients
IRB Number: AAAS2587
U.S. Govt. ID: NCT03875313
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine a safe and tolerable dose of CB-839 (an investigational drug), given together with talazoparib , and if it has an effect on your type of cancer. Subjects with advanced or metastatic (spread of cancer from the primary site to other places in the body) solid tumors will be included in this study.
This study is closed
Investigator
Kevin Kalinsky, MD, MS
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with advanced or metastatic solid tumors? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE